Ovid Therapeutics (OVID) Operating Expenses (2016 - 2026)

Ovid Therapeutics (OVID) has reported Operating Expenses for 11 consecutive years, with $16.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 44.83% year-over-year to $16.4 million; the trailing twelve-month figure through Jun 2026 stood at $59.9 million (up 24.31% YoY), and the FY2025 full-year result was $49.7 million, down 20.43% from the prior year.
• Operating Expenses declined to $16.4 million in Q2 2026 per OVID's latest filing, from $17.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $20.7 million in Q2 2024 and bottomed at $10.8 million in Q4 2024.
• Historically, Operating Expenses has averaged $14.6 million across 5 years, with a median of $13.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses sank 53.63% in 2022, then soared 50.01% in 2023.
• Over 5 years, Operating Expenses stood at $12.2 million in 2022, then jumped by 50.01% to $18.3 million in 2023, then tumbled by 41.09% to $10.8 million in 2024, then advanced by 20.49% to $13.0 million in 2025, then grew by 26.29% to $16.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $16.4 million, $17.8 million, and $13.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.